NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemotherapy (NAC) in stage II-IV rectal cancer. Dissecting the prognostic role of sidedness in metastatic colon cancer (mCC): ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback